HomeCompareAKRTF vs PFE

AKRTF vs PFE: Dividend Comparison 2026

AKRTF yields 6.77% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AKRTF wins by $36264.68M in total portfolio value
10 years
AKRTF
AKRTF
● Live price
6.77%
Share price
$4.69
Annual div
$0.32
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$36264.73M
Annual income
$35,263,365,836.29
Full AKRTF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — AKRTF vs PFE

📍 AKRTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAKRTFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AKRTF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AKRTF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AKRTF
Annual income on $10K today (after 15% tax)
$575.03/yr
After 10yr DRIP, annual income (after tax)
$29,973,860,960.85/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, AKRTF beats the other by $29,973,838,640.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AKRTF + PFE for your $10,000?

AKRTF: 50%PFE: 50%
100% PFE50/50100% AKRTF
Portfolio after 10yr
$18132.39M
Annual income
$17,631,696,047.50/yr
Blended yield
97.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

AKRTF
Analyst Ratings
3
Hold
Consensus: Hold
Altman Z
2.3
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AKRTF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAKRTFPFE
Forward yield6.77%6.13%
Annual dividend / share$0.32$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$36264.73M$49.6K
Annual income after 10y$35,263,365,836.29$26,258.71
Total dividends collected$36195.81M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold

Year-by-year: AKRTF vs PFE ($10,000, DRIP)

YearAKRTF PortfolioAKRTF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$12,053$1,353.00$9,153$693.39+$2.9KAKRTF
2$15,945$3,048.18$8,593$849.25+$7.4KAKRTF
3$24,598$7,537.25$8,336$1,066.78+$16.3KAKRTF
4$48,054$21,734.15$8,437$1,384.80+$39.6KAKRTF
5$130,781$79,362.67$9,013$1,875.40+$121.8KAKRTF
6$543,650$403,714.25$10,306$2,680.72+$533.3KAKRTF
7$3,718,568$3,136,862.53$12,820$4,101.38+$3.71MAKRTF
8$44,083,842$40,104,974.75$17,673$6,826.70+$44.07MAKRTF
9$935,855,449$888,685,737.97$27,543$12,591.86+$935.83MAKRTF
10$36,264,731,167$35,263,365,836.29$49,560$26,258.71+$36264.68MAKRTF

AKRTF vs PFE: Complete Analysis 2026

AKRTFStock

Aker Solutions ASA provides solutions, products, systems, and services to the oil and gas industry worldwide. It offers field planning, feasibility, and concept studies; specialist engineering, project management, and procurement services; floater designs, offshore wind, as well as engages in design, delivery, and construction of deepwater risers, oil, and gas production, and receiving and processing facilities. In addition, the company provides offshore fish farming, carbon capture, utilization and storage, hydrogen, and offshore wind solutions. Further, the company designs and constructs jackets for construction services and offers electrification services. Additionally, the company provides subsea production, compression, pump, power distribution, and processing systems, and subsea lifecycle services. Furthermore, the company offers maintenance, modifications, decommissioning, asset integrity management, hook-up, and completion solutions. Aker Solutions ASA was founded in 1841 and is headquartered in Fornebu, Norway.

Full AKRTF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this AKRTF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AKRTF vs SCHDAKRTF vs JEPIAKRTF vs OAKRTF vs KOAKRTF vs MAINAKRTF vs JNJAKRTF vs MRKAKRTF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.